Skip to content

Friday, July 26, 2024

Latest:

Reflections on medical advocacy
Congratulations, Dr. James R. Lupski, 2024 Mendel Lecturer and recipient of the Gilded Pea Award!
Benefits of low impact workouts: Pilates, dance and barre
Eating healthy on a budget: Tips and tricks from a registered dietitian
Defective serotonin 2C receptors lead to memory deficits in mice and humans

Home
Momentum
From The Labs
- About From the Labs
- Follow From The Labs on Twitter
Policywise
- About PolicyWise
- Follow @BCMEthics on Twitter
The Stitch
- About The Stitch
Progress Notes
bcm.edu

CDK4/6 inhibitor therapy

Interferon linked to ER+/HER- metastatic breast cancer resistance to therapy

March 12, 2021 CDK4/6 inhibitor therapy, endocrine therapy, ER+/HER2- breast cancer, Interferon, Metastatic breast cancer, Research, resistance to cancr treatment

Both preclinical models and tumor samples from patients with ER+/HER2- breast cancer link high IFN signaling to resistance to treatment.

From the Labs: Image of the Month

From the Labs: The wooly mammoth emerges from the past.

Healthy Habits: A DOC-umentary Series

Archives

Archives

Search

©1998 - 2023 Baylor College of Medicine®
One Baylor Plaza, Houston, Texas 77030
(713) 798-4951